The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Update on Accelerating Medicines Partnership

Update on Accelerating Medicines Partnership

May 17, 2019 • By From the College

  • Tweet
  • Email
Print-Friendly Version / Save PDF
stockish; everydayplus / shutterstock.com

stockish; everydayplus / shutterstock.com

The Accelerating Medicines Partnership (AMP) was launched in 2014 as a public-private partnership to spur development of new therapeutic options for rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Five years in, this unprecedented public-private effort is achieving its major milestones and yielding tools to accelerate potential new drug discoveries. The Rheumatology Research Foundation is a leading partner of the AMP RA/SLE program.

You Might Also Like
  • Accelerating Medicines Partnership Targets Therapies for Rheumatoid Arthritis, Systemic Lupus Erythematosus
  • Accelerating Medicines Partnership Shares Its Progress on RA/Lupus Network
  • Accelerating Medicines Partnership Advances Research for Autoimmune Diseases
Explore This Issue
May 2019
Also By This Author
  • ACR Leads Resolution to Address Copay Accumulator Policies at AMA House of Delegates Meeting

The program is working to define biological pathways with the goals of identifying biomarkers to predict pathological processes that lead to organ damage, and identifying potential new pathways or targets for drug development and intervention. The collaborative effort has made significant progress in ascertaining and defining biological pathways that link relevant molecular targets to clinical outcomes. Most notably, the AMP has created new technology standards for studying the cells responsible for RA and lupus.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“We are proud to be a partner of the AMP program and are thrilled with the discoveries already made through this collaboration. These advancements hold clues for potential research targets that may lead to future treatment options for millions of patients, and that’s critical to our mission of improving the health of everyone living with a rheumatic disease,” says Mary Wheatley, executive director of the Foundation.

The program is a pre-competitive partnership with the National Institutes of Health’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and National Institute of Allergy and Infectious Diseases (NIAID), the Foundation for the National Institutes of Health (FNIH), industry and not-for-profit organizations. Within the context of the partnership, the Foundation was actively involved in designing a bold, milestone-driven research plan and continues to share resources and expertise.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Currently in phase 2, the program is working to provide more information on how biological components correlate to disease activity and treatment responses. Visit www.NIH.gov for more information about the AMP RA/SLE program.

Filed Under: From the College, Rheumatoid Arthritis, SLE (Lupus) Tagged With: Rheumatology Research FoundationIssue: May 2019

You Might Also Like:
  • Accelerating Medicines Partnership Targets Therapies for Rheumatoid Arthritis, Systemic Lupus Erythematosus
  • Accelerating Medicines Partnership Shares Its Progress on RA/Lupus Network
  • Accelerating Medicines Partnership Advances Research for Autoimmune Diseases
  • Rheumatology Research Foundation Backs Need to Accelerate New Medicines for Lupus

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)